Premium
Epidemiology, Incidence, and Survival of Rhabdomyosarcoma Subtypes: SEER and ICES Database Analysis
Author(s) -
Amer Kamil M.,
Thomson Jennifer E.,
Congiusta Dominick,
Dobitsch Andrew,
Chaudhry Ahmed,
Li Matthew,
Chaudhry Aisha,
Bozzo Anthony,
Siracuse Brianna,
Aytekin Mahmut Nedim,
Ghert Michelle,
Beebe Kathleen S.
Publication year - 2019
Publication title -
journal of orthopaedic research®
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.041
H-Index - 155
eISSN - 1554-527X
pISSN - 0736-0266
DOI - 10.1002/jor.24387
Subject(s) - rhabdomyosarcoma , medicine , alveolar rhabdomyosarcoma , epidemiology , surveillance, epidemiology, and end results , survival analysis , oncology , embryonal rhabdomyosarcoma , proportional hazards model , incidence (geometry) , soft tissue sarcoma , population , survival rate , sarcoma , database , pathology , cancer registry , physics , environmental health , computer science , optics
Rhabdomyosarcoma is the most common soft‐tissue sarcoma in children and adolescents and accounts for 3% of all pediatric tumors. Subtypes include alveolar, spindle cell, embryonal, mixed‐type, pleomorphic, and rhabdomyosarcoma with ganglionic differentiation. The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database was queried for patients diagnosed with any type of rhabdomyosarcoma between 1973 and 2014. Patient demographics, tumor characteristics, and incidence were studied with χ 2 analysis. Survival was modeled with Kaplan–Meier survival curves and Cox proportional hazards models were used to assess the effect of age and gender on survival. Pleomorphic subtype had higher grade and larger sized tumors compared to other subtypes ( p < 0.05). Pleomorphic and alveolar rhabdomyosarcoma had the worst overall survival with a 26.6% and 28.9% 5‐year survival, respectively. Embryonal rhabdomyosarcoma had the highest 5‐year survival rate (73.9%). Tumor size was negatively correlated with survival months, indicating patients with larger tumors had shorter survival times ( p < 0.05). Presence of higher‐grade tumors and metastatic disease at presentation were negatively correlated with survival months ( p < 0.05). No significant differences in the survival were found between gender or race between all of the subtypes ( p > 0.05). This study highlights key differences in the demographic and survival rates of the different types of rhabdomyosarcoma that can be used for more tailored patient counseling. We also demonstrate that large, population‐level databases provide sufficient data that can be used in the analysis of rare tumors. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:2226–2230, 2019